

Study: ENGOT-ov84 / MK-2870-022

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.

MaNGO Sites list to be confirmed by Sponsor

Prov	City	Site	Principal Investigator	Active
BS	Brescia	Fondazione Poliambulanza	Chiara Abeni	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
MI	Milano	Ospedale di Niguarda	Giulia Carlo Stella	
MO	Modena	AOU Policlinico	Roberto Sabbatini	
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	
PI	Pisa	AOU Pisana	Carmelo Bengala	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	

* **MaNGO Principal Investigator to be defined**